New pricing framework for UK medicines agreed with industry

Tense  negotiations between the UK government and the pharmaceutical industry over a new drug pricing framework have concluded with a far-reaching agreement.

A  proposal from British drugmakers to establish a new Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has been successfully agreed, with the new framework set to run until the end of 2028.

The Association of the British Pharmaceutical Industry (ABPI) said the pricing deal would save the National Health Service (NHS) £14 billion ($17.5 billion) in medicine costs, while enabling patients to “access the latest lifesaving treatments more consistently.”